NewLink Genetics Corporation (NASDAQ: NLNK) today announced that indoximod, its leading drug development candidate, was granted orphan-drug designation by the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE